1. 2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC). (September 2015) Authors: Martens, U.M.; Wessendorf, S.; Knorrenschild, J. Riera; Buechner-Steudel, P.; Florschuetz, A.; Atzpodien, J.; Greeve, J.; Kanzler, S.; Ettrich, T.; Lindig, U.; Egger, M.; Hebart, H.; Geissler, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S344 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results. (October 2020) Authors: Sinn, M.; Liersch, T.; Riess, H.; Gellert, K.; Stübs, P.; Waldschmidt, D.; Lammert, F.; Maschmeyer, G.; Bechstein, W.; Bitzer, M.; Denzlinger, C.; Hofheinz, R.; Lindig, U.; Ghadimi, M.; Hinke, A.; Striefler, J.K.; Pelzer, U.; Bischoff, S.; Bahra, M.; Oettle, H. Journal: European journal of cancer Issue: Volume 138(2020) Page Start: 172 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗